News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
248,606 Results
Type
Article (15578)
Company Profile (34)
Press Release (232992)
Multimedia
Podcasts (29)
Webinars (7)
Section
Business (67835)
Career Advice (660)
Deals (11825)
Drug Delivery (44)
Drug Development (32590)
Employer Resources (73)
FDA (5736)
Job Trends (5040)
News (118366)
Policy (9590)
Tag
2027 Pharm Country Premier (1)
2027 Pharm Country Standard (2)
Academia (1204)
Academic (1)
Accelerated approval (18)
ADA (17)
Adcomms (15)
Allergies (84)
Alliances (17350)
ALS (95)
Alzheimer's disease (602)
Antibody-drug conjugate (ADC) (177)
Approvals (6008)
Artificial intelligence (196)
ASCO (137)
Autoimmune disease (107)
Automation (18)
Bankruptcy (82)
Best Places to Work (4199)
BIOSECURE Act (8)
Biosimilars (102)
Biotechnology (16)
Bladder cancer (85)
Brain cancer (30)
Breast cancer (287)
Cancer (2253)
Cardiovascular disease (214)
Career advice (576)
Career pathing (21)
CAR-T (110)
CDC (29)
Celiac Disease (2)
Cell therapy (287)
Cervical cancer (21)
Clinical research (29845)
Collaboration (691)
Commercialization (1)
Company closure (2)
Compensation (180)
Complete response letters (21)
COVID-19 (1302)
CRISPR (37)
C-suite (412)
Cystic fibrosis (39)
Data (3534)
Decentralized trials (1)
Denatured (13)
Depression (50)
Dermatology (42)
Diabetes (277)
Diagnostics (2339)
Digital health (20)
Diversity (10)
Diversity, equity & inclusion (31)
Drug discovery (99)
Drug pricing (64)
Drug shortages (19)
Duchenne muscular dystrophy (111)
Earnings (26536)
Editorial (31)
Employer branding (5)
Employer resources (69)
Events (33988)
Executive appointments (404)
FDA (7166)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (4)
Frontotemporal dementia (5)
Funding (628)
Gene editing (66)
Generative AI (15)
Gene therapy (255)
GLP-1 (423)
Government (1464)
Grass and pollen (3)
Guidances (182)
Healthcare (6708)
Hematology (84)
HIV (48)
Huntington's disease (22)
IgA nephropathy (40)
Immunology and inflammation (90)
Immuno-oncology (32)
Indications (73)
Infectious disease (1461)
Inflammatory bowel disease (93)
Inflation Reduction Act (6)
Influenza (64)
Intellectual property (64)
Interviews (112)
IPO (4833)
IRA (23)
Job creations (1021)
Job search strategy (486)
JPM (18)
Kidney cancer (8)
Labor market (31)
Layoffs (134)
Leadership (23)
Legal (1855)
Liver cancer (45)
Longevity (8)
Lung cancer (298)
Lymphoma (223)
Machine learning (17)
Management (25)
Manufacturing (368)
Marketing (1)
MASH (102)
Medical affairs (1)
Medical device (4472)
Medtech (4522)
Mergers & acquisitions (7474)
Metabolic disorders (638)
mRNA (58)
Multiple sclerosis (105)
NASH (16)
Neurodegenerative disease (132)
Neuropsychiatric disorders (28)
Neuroscience (1201)
NextGen: Class of 2026 (2372)
Non-profit (1959)
Now hiring (10)
Obesity (254)
Opinion (77)
Ovarian cancer (92)
Pain (81)
Pancreatic cancer (85)
Parkinson's disease (148)
Partnered (15)
Patents (97)
Patient recruitment (246)
Peanut (29)
People (22796)
Pharmaceutical (13)
Pharmacy benefit managers (15)
Phase 1 (6947)
Phase 2 (12895)
Phase 3 (12020)
Pipeline (3535)
Policy (134)
Postmarket research (1210)
Preclinical (2508)
Press Release (44)
Prostate cancer (142)
Psychedelics (24)
Radiopharmaceuticals (119)
Rare diseases (411)
Real estate (2089)
Recruiting (24)
Regulatory (8349)
Reports (24)
Research institute (1087)
Resumes & cover letters (89)
Rett syndrome (6)
RNA editing (3)
RSV (49)
Schizophrenia (72)
Series A (132)
Series B (79)
Service/supplier (4)
Sickle cell disease (38)
Special edition (5)
Spinal muscular atrophy (77)
Sponsored (15)
Startups (1504)
Stomach cancer (6)
Supply chain (44)
Tariffs (20)
The Weekly (16)
Vaccines (528)
Venture capital (41)
Weight loss (167)
Women's health (61)
Worklife (10)
Date
Today (26)
Last 7 days (164)
Last 30 days (893)
Last 365 days (10214)
2026 (5078)
2025 (10437)
2024 (12415)
2023 (13207)
2022 (20848)
2021 (21380)
2020 (19853)
2019 (16990)
2018 (12766)
2017 (11656)
2016 (11331)
2015 (13615)
2014 (9539)
2013 (7629)
2012 (8450)
2011 (9038)
2010 (7761)
Location
Africa (313)
Alabama (17)
Alaska (5)
Arizona (93)
Arkansas (2)
Asia (19471)
Australia (3156)
California (4335)
Canada (1095)
China (708)
Colorado (174)
Connecticut (188)
Delaware (221)
Europe (41096)
Florida (566)
Georgia (168)
Idaho (16)
Illinois (428)
India (56)
Indiana (222)
Iowa (3)
Japan (335)
Kansas (45)
Kentucky (21)
Louisiana (19)
Maine (12)
Maryland (504)
Massachusetts (3002)
Michigan (151)
Minnesota (243)
Missouri (76)
Montana (7)
Nebraska (8)
Nevada (47)
New Hampshire (16)
New Jersey (1424)
New Mexico (7)
New York (1172)
North Carolina (459)
North Dakota (1)
Northern California (2115)
Ohio (113)
Oklahoma (5)
Oregon (4)
Pennsylvania (984)
Puerto Rico (10)
Rhode Island (8)
South America (426)
South Carolina (12)
Southern California (1822)
Tennessee (61)
Texas (513)
United States (15530)
Utah (133)
Virginia (79)
Washington D.C. (9)
Washington State (430)
Wisconsin (37)
Wyoming (2)
248,606 Results for "menarini asia pacific group formerly invida group".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress
June 15, 2026
·
7 min read
Press Releases
Menarini Group Announces New Data at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
May 14, 2026
·
20 min read
Press Releases
Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress
June 15, 2026
·
12 min read
Press Releases
Menarini Group Presents New Data from the Phase 1b/2 ELEVATE Study of Elacestrant in Combination with Capivasertib in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
May 28, 2026
·
8 min read
Press Releases
Menarini Group Presents New Data from the Phase 1b/2 ELEVATE Study of Elacestrant (ORSERDU®) in Combination with Capivasertib in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
May 28, 2026
·
10 min read
Government
PhMRA’s long-standing leader Steve Ubl to leave lobby group by year-end
Industry leader Steve Ubl has served as PhRMA’s CEO for more than a decade, the longest tenure of any head of the trade group.
April 9, 2026
·
2 min read
·
Tristan Manalac
Press Releases
Insilico Medicine Receives USD 5million Milestone Payment from Menarini Group Following First-in-Human (FIH) Achievement for MEN2501
February 4, 2026
·
4 min read
Press Releases
Avance Clinical Announces Asia Pacific and Mainland China Expansion Ahead of BIO International Convention 2026
June 19, 2026
·
3 min read
Rare diseases
Rare Disease Groups Lobby for Regulatory Expediency as Makary Defends ‘Rigorous’ Approach
This week’s Capitol Hill meetings come on the heels of rejections of ultra-rare disease drugs developed by Biohaven and Saol Therapeutics. Physicians and patient groups implored the FDA to expedite these treatments.
February 27, 2026
·
6 min read
·
Heather McKenzie
Press Releases
Chiesi Group Completes Acquisition of KalVista Pharmaceuticals
June 11, 2026
·
8 min read
1 of 24,861
Next
